Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070902 | 0.89 | LMNA (0.53) | LMNAPOLBSIRT1BCL2MCL1 | |
| SCHEMBL4061329 | 0.76 | BCL2 (0.50) | LMNAALDH1A1BCL2MCL1KMT2A | |
| SCHEMBL15214045 | 0.76 | NR4A1 (0.61) | ALDH1A1BCL2MCL1KMT2AMAPT | |
| SCHEMBL4534920 | 0.75 | BCL2 (0.47) | LMNASIRT1BCL2MCL1KMT2A | |
| SCHEMBL29382216 | 0.75 | MAPT (0.57) | LMNAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL8945912 | 0.75 | MAPT (0.57) | LMNAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL27538691 | 0.75 | LMNA (0.53) | LMNAPOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL2417465 | 0.74 | GABRA1 (0.70) | LMNABCL2MCL1CNR1CNR2 | |
| SCHEMBL11494893 | 0.74 | MAPK1 (0.48) | LMNAPOLBSIRT1KMT2AMEN1 | |
| SCHEMBL4516868 | 0.74 | BCL2 (0.46) | LMNASIRT1ALDH1A1BCL2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270470-A1 | Compounds I | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
| EP-1881950-A1 | NEW COMPOUNDS I | AstraZeneca AB (SE) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006121391-A1 | NEW COMPOUNDS I | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270470-A1 | Compounds I | F12, F11, F5 | LMNA 869/4885POLB 2540/4885SIRT1 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.